1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Rhenman & Partners Asset Management AB Buys LivaNova PLC, Exact Sciences Corp, Abiomed Inc, Sells Biogen Inc, Medtronic PLC, Gilead Sciences Inc

Stockholm, V7, based Investment company Rhenman & Partners Asset Management AB buys LivaNova PLC, Exact Sciences Corp, Abiomed Inc, Macrogenics Inc, Nektar Therapeutics Inc, Dermira Inc, Amarin Corp PLC, Esperion Therapeutics Inc, Biomarin Pharmaceutical Inc, Centene Corp, Intra-Cellular Therapies Inc, Madrigal Pharmaceuticals Inc, Ra Pharmaceuticals Inc, Xencor Inc, Aimmune Therapeutics Inc, Acceleron Pharma Inc, Mirati Therapeutics Inc, NanoString Technologies Inc, Immunomedics Inc, Qiagen NV, Dynavax Technologies Corp, Coherus BioSciences Inc, Epizyme Inc, G1 Therapeutics Inc, Symantec Corp, Alphabet Inc, sells Biogen Inc, Medtronic PLC, Gilead Sciences Inc, Incyte Corp, Exelixis Inc, Celgene Corp, AbbVie Inc, Alexion Pharmaceuticals Inc, Becton, Dickinson and Co, Sage Therapeutics Inc, Bristol-Myers Squibb Company, bluebird bio Inc, Edwards Lifesciences Corp, Arena Pharmaceuticals Inc, FibroGen Inc, Seattle Genetics Inc, Portola Pharmaceuticals Inc, Flexion Therapeutics Inc, Mednax Inc, Spark Therapeutics Inc, Sangamo Therapeutics Inc, Iovance Biotherapeutics Inc, Eli Lilly and Co, Alkermes PLC, Adamas Pharmaceuticals Inc, Laboratory Corp of America Holdings, Loxo Oncology Inc, Chimerix Inc, Achillion Pharmaceuticals Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Rhenman & Partners Asset Management AB. As of 2019Q1, Rhenman & Partners Asset Management AB owns 93 stocks with a total value of $855 million. These are the details of the buys and sells.

For the details of Rhenman & Partners Asset Management AB's stock buys and sells, go to https://www.gurufocus.com/guru/rhenman+%26+partners+asset+management+ab/current-portfolio/portfolio

These are the top 5 holdings of Rhenman & Partners Asset Management AB
  1. UnitedHealth Group Inc (UNH) - 123,400 shares, 3.57% of the total portfolio. Shares reduced by 2.37%
  2. Jazz Pharmaceuticals PLC (JAZZ) - 187,171 shares, 3.13% of the total portfolio. Shares added by 12.88%
  3. Vertex Pharmaceuticals Inc (VRTX) - 144,400 shares, 3.11% of the total portfolio. Shares added by 9.04%
  4. Abiomed Inc (ABMD) - 92,493 shares, 3.09% of the total portfolio. Shares added by 41.62%
  5. Cigna Corp (CI) - 159,691 shares, 3.00% of the total portfolio.
New Purchase: Exact Sciences Corp (EXAS)

Rhenman & Partners Asset Management AB initiated holding in Exact Sciences Corp. The purchase prices were between $61.98 and $96.5, with an estimated average price of $84.73. The stock is now traded at around $95.15. The impact to a portfolio due to this purchase was 1.01%. The holding were 100,000 shares as of .

New Purchase: Dermira Inc (DERM)

Rhenman & Partners Asset Management AB initiated holding in Dermira Inc. The purchase prices were between $6.19 and $14.13, with an estimated average price of $8.29. The stock is now traded at around $13.70. The impact to a portfolio due to this purchase was 0.79%. The holding were 500,329 shares as of .

New Purchase: Madrigal Pharmaceuticals Inc (MDGL)

Rhenman & Partners Asset Management AB initiated holding in Madrigal Pharmaceuticals Inc. The purchase prices were between $103.48 and $143.84, with an estimated average price of $124.23. The stock is now traded at around $142.50. The impact to a portfolio due to this purchase was 0.4%. The holding were 27,225 shares as of .

New Purchase: Ra Pharmaceuticals Inc (RARX)

Rhenman & Partners Asset Management AB initiated holding in Ra Pharmaceuticals Inc. The purchase prices were between $18.2 and $27.22, with an estimated average price of $21.4. The stock is now traded at around $23.45. The impact to a portfolio due to this purchase was 0.39%. The holding were 150,000 shares as of .

New Purchase: Aimmune Therapeutics Inc (AIMT)

Rhenman & Partners Asset Management AB initiated holding in Aimmune Therapeutics Inc. The purchase prices were between $21.15 and $26.37, with an estimated average price of $23.55. The stock is now traded at around $22.29. The impact to a portfolio due to this purchase was 0.39%. The holding were 149,201 shares as of .

New Purchase: Acceleron Pharma Inc (XLRN)

Rhenman & Partners Asset Management AB initiated holding in Acceleron Pharma Inc. The purchase prices were between $39.06 and $48.05, with an estimated average price of $43.83. The stock is now traded at around $44.74. The impact to a portfolio due to this purchase was 0.38%. The holding were 70,000 shares as of .

Added: LivaNova PLC (LIVN)

Rhenman & Partners Asset Management AB added to a holding in LivaNova PLC by 99.50%. The purchase prices were between $86.15 and $100.49, with an estimated average price of $93.42. The stock is now traded at around $69.92. The impact to a portfolio due to this purchase was 1.37%. The holding were 240,600 shares as of .

Added: Abiomed Inc (ABMD)

Rhenman & Partners Asset Management AB added to a holding in Abiomed Inc by 41.62%. The purchase prices were between $276.39 and $362.25, with an estimated average price of $332.72. The stock is now traded at around $280.54. The impact to a portfolio due to this purchase was 0.91%. The holding were 92,493 shares as of .

Added: Macrogenics Inc (MGNX)

Rhenman & Partners Asset Management AB added to a holding in Macrogenics Inc by 78.39%. The purchase prices were between $11.11 and $25.6, with an estimated average price of $17.21. The stock is now traded at around $18.34. The impact to a portfolio due to this purchase was 0.89%. The holding were 967,186 shares as of .

Added: Nektar Therapeutics Inc (NKTR)

Rhenman & Partners Asset Management AB added to a holding in Nektar Therapeutics Inc by 42.61%. The purchase prices were between $31.58 and $46.35, with an estimated average price of $39.54. The stock is now traded at around $35.83. The impact to a portfolio due to this purchase was 0.86%. The holding were 734,445 shares as of .

Added: Amarin Corp PLC (AMRN)

Rhenman & Partners Asset Management AB added to a holding in Amarin Corp PLC by 270.80%. The purchase prices were between $12.61 and $22.33, with an estimated average price of $17.95. The stock is now traded at around $19.46. The impact to a portfolio due to this purchase was 0.66%. The holding were 370,800 shares as of .

Added: Esperion Therapeutics Inc (ESPR)

Rhenman & Partners Asset Management AB added to a holding in Esperion Therapeutics Inc by 35.54%. The purchase prices were between $40.11 and $53.57, with an estimated average price of $44.86. The stock is now traded at around $42.89. The impact to a portfolio due to this purchase was 0.59%. The holding were 479,767 shares as of .

Sold Out: Biogen Inc (BIIB)

Rhenman & Partners Asset Management AB sold out a holding in Biogen Inc. The sale prices were between $216.71 and $338.96, with an estimated average price of $315.3.

Sold Out: Gilead Sciences Inc (GILD)

Rhenman & Partners Asset Management AB sold out a holding in Gilead Sciences Inc. The sale prices were between $62.53 and $70.05, with an estimated average price of $66.46.

Sold Out: Portola Pharmaceuticals Inc (PTLA)

Rhenman & Partners Asset Management AB sold out a holding in Portola Pharmaceuticals Inc. The sale prices were between $17.93 and $34.72, with an estimated average price of $28.71.

Sold Out: Mednax Inc (MD)

Rhenman & Partners Asset Management AB sold out a holding in Mednax Inc. The sale prices were between $27.12 and $36.86, with an estimated average price of $33.62.

Sold Out: Spark Therapeutics Inc (ONCE)

Rhenman & Partners Asset Management AB sold out a holding in Spark Therapeutics Inc. The sale prices were between $37.95 and $113.98, with an estimated average price of $72.19.

Sold Out: Laboratory Corp of America Holdings (LH)

Rhenman & Partners Asset Management AB sold out a holding in Laboratory Corp of America Holdings. The sale prices were between $123.7 and $156.3, with an estimated average price of $143.14.

Reduced: Medtronic PLC (MDT)

Rhenman & Partners Asset Management AB reduced to a holding in Medtronic PLC by 43.79%. The sale prices were between $82.45 and $93.79, with an estimated average price of $89.53. The stock is now traded at around $88.63. The impact to a portfolio due to this sale was -1.37%. Rhenman & Partners Asset Management AB still held 168,842 shares as of .

Reduced: Incyte Corp (INCY)

Rhenman & Partners Asset Management AB reduced to a holding in Incyte Corp by 62.46%. The sale prices were between $63.56 and $88.17, with an estimated average price of $81.08. The stock is now traded at around $83.41. The impact to a portfolio due to this sale was -1.21%. Rhenman & Partners Asset Management AB still held 100,000 shares as of .

Reduced: Exelixis Inc (EXEL)

Rhenman & Partners Asset Management AB reduced to a holding in Exelixis Inc by 55.16%. The sale prices were between $19.6 and $24.76, with an estimated average price of $22.74. The stock is now traded at around $24.19. The impact to a portfolio due to this sale was -1.19%. Rhenman & Partners Asset Management AB still held 430,000 shares as of .

Reduced: Celgene Corp (CELG)

Rhenman & Partners Asset Management AB reduced to a holding in Celgene Corp by 69.54%. The sale prices were between $64.09 and $94.34, with an estimated average price of $87.12. The stock is now traded at around $94.33. The impact to a portfolio due to this sale was -1.1%. Rhenman & Partners Asset Management AB still held 65,698 shares as of .

Reduced: AbbVie Inc (ABBV)

Rhenman & Partners Asset Management AB reduced to a holding in AbbVie Inc by 63.06%. The sale prices were between $77.14 and $92.19, with an estimated average price of $82.08. The stock is now traded at around $82.95. The impact to a portfolio due to this sale was -1.08%. Rhenman & Partners Asset Management AB still held 60,000 shares as of .

Reduced: Alexion Pharmaceuticals Inc (ALXN)

Rhenman & Partners Asset Management AB reduced to a holding in Alexion Pharmaceuticals Inc by 40.78%. The sale prices were between $97.36 and $137.75, with an estimated average price of $123.89. The stock is now traded at around $141.30. The impact to a portfolio due to this sale was -1.04%. Rhenman & Partners Asset Management AB still held 136,466 shares as of .



Here is the complete portfolio of Rhenman & Partners Asset Management AB. Also check out:

1. Rhenman & Partners Asset Management AB's Undervalued Stocks
2. Rhenman & Partners Asset Management AB's Top Growth Companies, and
3. Rhenman & Partners Asset Management AB's High Yield stocks
4. Stocks that Rhenman & Partners Asset Management AB keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK